Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults

被引:104
作者
Schwarz, Tino F. [1 ]
Horacek, Thomas
Knuf, Markus [2 ]
Damman, Hanns-Gerd [3 ]
Roman, Francois
Drame, Mamadou
Gillarde, Paul
Jilg, Wolfgang [4 ]
机构
[1] Stiftung Juliusspital, D-97070 Wurzburg, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Pediat, Mainz, Germany
[3] Clin Res Inst Schwerin, Schwerin, Germany
[4] Univ Regensburg, D-8400 Regensburg, Germany
关键词
H5N1; Pre-pandemic vaccination; Adjuvant; CROSS-REACTIVE IMMUNITY; PANDEMIC INFLUENZA; VIRUS H5N1; IMMUNOGENICITY; SAFETY;
D O I
10.1016/j.vaccine.2009.01.040
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the Causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 mu g of HA, followed by a 6-month booster with a vaccine formulated with 3.75 mu g HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N=48-60) of adults aged 18-60 years who received a single booster administration of either A/Indonesia/05/2005 or A/Vietnam/1194/2004 vaccine 6 months after a 1- or 2-dose (given 21 days apart) primary vaccination with A/Vietnam/1194/2004. All prime-boost schedules assessed induced early (7 days post-booster) humoral responses that met regulatory acceptance criteria. Two doses of A/Vietnam/1194/2004 given 6 months apart achieved equivalent homologous seroprotection after the second vaccination (89.6%), when compared to two doses given 21 days apart (92.7-93.2%). Remarkably, two doses of A/Vietnam/1194/2004 given 6 months apart induced a higher cross-reactive seroprotection against A/Indonesia/05/2005 (83.3%) when compared to two doses given 21 days apart (41.5-54.5%). A 6-month A/Indonesia/05/2005 booster dose after one primary dose of A/Vietnam/1194/2004 vaccine induced 92.5% seroprotection against A/Indonesia/05/2005 and 98.1% against A/Vietnam/1194/2004. Since a single booster 6 months after one primary dose of AS03-adjuvanted vaccine induces strong and rapid seroprotective immune response against both homologous and heterologous H5N1 strains, these results might have important implications for public health strategy aiming to organize vaccination campaigns with pre-pandemic vaccines. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6284 / 6290
页数:7
相关论文
共 30 条
[1]  
Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
[2]  
[Anonymous], 2007, GUID IND CLIN DAT NE
[3]   Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine [J].
Baras, Benoit ;
Stittelaar, Koert J. ;
Simon, James H. ;
Thoolen, Robert J. M. M. ;
Mossman, Sally P. ;
Pistoor, Frank H. M. ;
van Amerongen, Geert ;
Wettendorff, Martine A. ;
Hanon, Emmanuel ;
Osterhaus, Albert D. M. E. .
PLOS ONE, 2008, 3 (01)
[4]   Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults [J].
Bernstein, David I. ;
Edwards, Kathryn M. ;
Dekker, Cornelia L. ;
Belshe, Robert ;
Talbot, Helen K. B. ;
Graham, Irene L. ;
Noah, Diana L. ;
He, Fenhua ;
Hill, Heather .
JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (05) :667-675
[5]   A clinical trial of a whole-virus H5N1 vaccine derived from cell culture [J].
Ehrlich, Hartmut J. ;
Mueller, Markus ;
Oh, Helen M. L. ;
Tambyah, Paul A. ;
Joukhadar, Christian ;
Montomoli, Emanuele ;
Fisher, Dale ;
Berezuk, Greg ;
Fritsch, Sandor ;
Loew-Baselli, Alexandra ;
Vartian, Nina ;
Bobrovsky, Roman ;
Pavlova, Borislava G. ;
Poellabauer, Eva Maria ;
Kistner, Otfried ;
Barrett, P. Noel .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2573-2584
[6]   Pandemic H5N1 influenza vaccine development: an update [J].
El Sahlyt, Hana M. ;
Keitel, Wendy A. .
EXPERT REVIEW OF VACCINES, 2008, 7 (02) :241-247
[7]  
*EUR COMM PROP MED, 2007, EMEACHMPVWP263499200
[8]  
European committee for proprietary medicinal products, 2004, CPMPVEG471703 EUR CO
[9]   Strategies for mitigating an influenza pandemic [J].
Ferguson, Neil M. ;
Cummings, Derek A. T. ;
Fraser, Christophe ;
Cajka, James C. ;
Cooley, Philip C. ;
Burke, Donald S. .
NATURE, 2006, 442 (7101) :448-452
[10]   Human infection with highly pathogenic H5N1 influenza virus [J].
Gambotto, Andrea ;
Barratt-Boyes, Simon M. ;
de Jong, Menno D. ;
Neumann, Gabriele ;
Kawaoka, Yoshihiro .
LANCET, 2008, 371 (9622) :1464-1475